Our Pricing

Wegovy Pill UK: Expert Guide to Oral Semaglutide Tablets

The wegovy pill uk online pharmacy market has transformed with the arrival of oral semaglutide tablets, offering a needle-free alternative to the well-established Wegovy injection. At Cured Pharmacy, our UK-registered clinical team can assess your suitability for Wegovy® Oral Tablets from £79.00, providing the same active ingredient as the injection but in a convenient daily tablet format. This comprehensive guide answers the most common questions we receive from patients considering this new formulation.

What Is the Wegovy Pill and How Does It Work?

Wegovy® Oral Tablets contain semaglutide, a GLP-1 receptor agonist that mimics a natural hormone your body produces after eating [1]. Unlike the injectable form that's been available since 2021, the oral tablet delivers semaglutide through the digestive system using a special absorption enhancer called SNAC (salcaprozate sodium), which helps the medication cross the stomach lining into your bloodstream [2].

Once absorbed, semaglutide works by slowing gastric emptying, reducing appetite signals in the brain, and improving insulin secretion when blood sugar rises [1]. Clinical trials demonstrate that oral semaglutide produces significant weight reduction when combined with a reduced-calorie diet and increased physical activity, with participants in the OASIS 1 trial achieving an average weight loss of 15.1% over 68 weeks compared to 2.4% with placebo [3].

The oral formulation offers identical therapeutic benefits to the injection but requires daily administration on an empty stomach, whereas the injection is administered once weekly. Both formulations are prescription-only medications in the UK and must be prescribed by a registered healthcare professional following clinical assessment.

Wegovy Pill vs Wegovy Injection: Key Differences

From a clinical efficacy perspective, both formulations demonstrate substantial weight reduction in trials, though head-to-head comparison studies are limited. The STEP trials for injectable semaglutide showed average weight loss of 14.9% at 68 weeks on the 2.4mg dose [4], while the OASIS 1 trial for oral semaglutide demonstrated 15.1% average weight loss at the 50mg daily dose [3].

Patient preference often determines the best choice. Some individuals prefer the convenience of a weekly injection and find it easier to maintain adherence, while others have needle phobia or simply prefer incorporating a daily tablet into their morning routine. During your consultation at Cured Pharmacy, our UK prescribers will discuss which formulation aligns better with your lifestyle and medical history.

Administration and Dosing Schedule

The most obvious difference is administration method. Wegovy oral tablets are taken once daily, at least 30 minutes before your first food, drink, or other medications of the day, with no more than 120ml of plain water [2]. The injection, by contrast, is administered subcutaneously once weekly at any time of day, with or without food.

Both formulations follow a gradual dose escalation schedule to minimise gastrointestinal side effects. The oral tablet typically starts at 3mg daily and increases every four weeks up to a maintenance dose of 14mg daily, while the injection begins at 0.25mg weekly and escalates to 2.4mg weekly over 16-20 weeks [1][2].

Who Can Take the Wegovy Pill in the UK?

Pregnancy and breastfeeding are absolute contraindications, as semaglutide has not been studied in these populations and animal studies suggest potential foetal harm [2]. Women of childbearing potential should use effective contraception during treatment and discontinue semaglutide at least two months before a planned pregnancy.

Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), emphasises that the online consultation process at Cured Pharmacy thoroughly screens for these contraindications. The assessment takes under three minutes but covers your complete medical history, current medications, and specific risk factors. Only if a UK prescriber determines the treatment is clinically appropriate and safe will a prescription be issued.

Eligibility Criteria for Oral Semaglutide

Wegovy oral tablets are licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [2]. These criteria align with NICE guidance for weight management interventions and match the eligibility requirements for injectable Wegovy.

However, not everyone who meets the BMI criteria can safely take semaglutide. The medication is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1]. It should be used with caution in individuals with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy.

Common Side Effects and How to Manage Them

The most frequently reported side effects of oral semaglutide are gastrointestinal in nature, including nausea, diarrhoea, vomiting, constipation, and abdominal pain [3]. In the OASIS 1 trial, nausea occurred in approximately 44% of participants on oral semaglutide compared to 16% on placebo, though most cases were mild to moderate and diminished over time as the body adjusted to the medication [3].

These side effects are why both oral and injectable semaglutide follow a gradual dose escalation protocol. Starting at a lower dose and increasing slowly every four weeks allows your digestive system to adapt. Practical strategies to minimise gastrointestinal symptoms include eating smaller, more frequent meals, avoiding high-fat or spicy foods, staying well-hydrated, and taking the tablet at the same time each morning on a completely empty stomach.

More serious but rare side effects include pancreatitis (inflammation of the pancreas), gallbladder problems, kidney injury secondary to dehydration from vomiting or diarrhoea, and changes in vision [1][2]. If you experience severe abdominal pain that doesn't resolve, persistent vomiting, or sudden vision changes, you should seek medical attention immediately. Hypoglycaemia (low blood sugar) is uncommon with semaglutide alone but can occur if you're also taking other diabetes medications such as insulin or sulfonylureas.

Wegovy Pill Price UK and How to Order from Cured Pharmacy

Once your prescription is approved, your medication is dispensed by our GPhC-registered pharmacy (registration number 9012511) and dispatched in 100% discreet packaging. We source only genuine UK-licensed medications directly from licensed wholesalers, never grey-market imports or unlicensed products. Delivery is typically next-day for orders placed before our cut-off time, though you can select your preferred delivery option at checkout.

We guarantee the lowest prices in the UK for weight loss medications. If you find a lower price from another UK-registered pharmacy for the same product and dose, we'll match it. Our commitment to competitive pricing, combined with our transparent consultation process and genuine medications, makes Cured Pharmacy a trusted choice for thousands of UK patients managing their weight with prescription treatments.

Transparent Pricing and Prescription Process

At Cured Pharmacy, Wegovy® Oral Tablets are available from £79.00, with the final price determined by your prescribed dose and treatment duration. Unlike many online pharmacies, we display pricing upfront before you begin the consultation process, ensuring complete transparency with no hidden fees or surprise charges at checkout.

The ordering process is straightforward and fully compliant with UK pharmacy regulations. You start by completing a free online clinical consultation that takes under three minutes, covering your medical history, current medications, weight loss goals, and any contraindications. A UK-registered prescriber reviews your assessment, typically within hours, and if clinically appropriate, issues a prescription electronically to our pharmacy.

Comparing All Weight Loss Treatment Options at Cured Pharmacy

For patients who cannot take or do not respond to GLP-1 medications, Orlistat-based treatments offer an alternative mechanism of action. Orlistat works by blocking approximately 30% of dietary fat absorption in the intestines, leading to modest weight loss when combined with a reduced-calorie, lower-fat diet [6]. It's available in prescription strength (Orlistat 120mg, Xenical) and over-the-counter strength (Alli 60mg, Orlos 60mg).

The choice between these options depends on your medical history, weight loss goals, lifestyle preferences, and budget. During your consultation, our UK prescribers consider all these factors to recommend the most appropriate treatment. Many patients start with one medication and switch to another if side effects are problematic or weight loss plateaus, which is a normal part of long-term weight management.

Injectable GLP-1 Receptor Agonists

Beyond oral semaglutide, Cured Pharmacy offers several injectable GLP-1 treatments, each with distinct characteristics. Wegovy injection (semaglutide 2.4mg weekly) remains the most prescribed GLP-1 for weight management in the UK, offering the convenience of once-weekly administration with proven efficacy from the landmark STEP trials [4].

Mounjaro (tirzepatide) represents the newest class of weight loss medication, functioning as a dual GIP/GLP-1 receptor agonist. The SURMOUNT-1 trial demonstrated that tirzepatide produced average weight reductions of up to 22.5% at the highest dose over 72 weeks, exceeding results seen with semaglutide in similar populations [5]. Saxenda (liraglutide 3mg daily) is an older GLP-1 option requiring daily injection but with a well-established safety profile and lower cost entry point.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Novo Nordisk. (2024). Wegovy (semaglutide) Oral Tablets: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/
3. Knop, F. K., et al. (2023). Oral Semaglutide 50 mg Taken Once per Day in Adults with Overweight or Obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 402(10403), 705–719. https://doi.org/10.1016/S0140-6736(23)01185-6
4. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
5. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
6. Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment, dietary modifications, and physical activity levels.